For a menopause-related search, choose a source category below. These categories also contain products for other uses; they are not a list of suitable treatments.
HORMONES AND SUBSTITUTES
Browse ingredients, then choose a strength and product. Ontario inventory only; not a treatment recommendation.
MEDROXYPROGESTERONE ACETATE: products 1 to 10 of 10.
Prices below are the ministry's recorded amounts per source unit, not pharmacy quotes or the patient's payment. Different strengths, forms and package units are not directly comparable. The cost plan asks for quantity and refill details.
| Product / strength / form | Ontario listing | Recorded ministry price | Next step |
|---|---|---|---|
| AA-Medroxy 100mg TabDIN 02267640 | General benefit | $1.2057per source unit | Requirements & sourcesBuild cost plan |
| AA-Medroxy 10mg TabDIN 02277298 | General benefit | $0.5649per source unit | Requirements & sourcesBuild cost plan |
| AA-Medroxy 2.5mg TabDIN 02244726 | General benefit | $0.1301per source unit | Requirements & sourcesBuild cost plan |
| AA-Medroxy 5mg TabDIN 02244727 | General benefit | $0.2602per source unit | Requirements & sourcesBuild cost plan |
| Depo-Provera 150mg/mL Inj Sol-1mL Pref SyrDIN 02523493 | Temporary benefit | $34.7886per source unit | Requirements & sourcesBuild cost plan |
| Depo-Provera 150mg/mL Inj Sol-1mL Pref SyrDIN 09858134 | Temporary benefit | $31.6900per source unit | Requirements & sourcesBuild cost plan |
| Provera 100mg TabDIN 00030945 | Listed, not a benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Provera 10mg TabDIN 00729973 | General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada | $0.5649per source unit | Requirements & sourcesBuild cost plan |
| Provera 2.5mg TabDIN 00708917 | General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada | $0.1301per source unit | Requirements & sourcesBuild cost plan |
| Provera 5mg TabDIN 00030937 | General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada | $0.2602per source unit | Requirements & sourcesBuild cost plan |
Not seeing a product? Search Canadian records by medication name or DIN. Absence from this Ontario extract does not establish non-coverage. Open an exact product for its dated Health Canada status; a listing is not a stock check.
Class sources and program rules
Ontario Ministry of Health: odb-formulary-ed43-extract-2026-08-26.xml, extract 2026-08-26. Ontario class index: formulary-ed43-front-matter.txt, Part V.
68:00 HORMONES AND SUBSTITUTES.
68:04 Corticosteroids.
68:08 Androgens.
68:12 Contraceptives.
68:16 Estrogens.
68:20:02 Oral Anti-Diabetic Agents.
68:20:06 Incretin Mimetics.
68:20:10 Insulins (Rapid Acting).
68:20:12 Insulins (Intermediate Acting).
68:20:14 Insulins (Long Acting).
68:20:16 Insulins (Pre-Mixed).
68:24 Parathyroid Agents.
68:28 Pituitary Agents.
68:32 Progestogens and Oral Contraceptives.
68:36 Thyroids.
68:38 Anti-Thyroids.
National Defence, WDH Guide to Menopause, 2026-09-17
Hormone Therapy (HT) previously called Hormone Replacement Therapy replaces estrogen and when needed, progesterone
Ontario Drug Benefit Formulary, Part V, 2026-09-03, p. 38
68:16 Estrogens
68:32 Progestogens and Oral Contraceptives